Mostrando 3,721 - 3,740 Resultados de 5,191 Para Buscar '"RBD"', tiempo de consulta: 0.85s Limitar resultados
  1. 3721
    “…Seroconversion was observed in all vaccinated participants, who showed high antibody titers against RBD, Spike, and neutralizing activity against the Wuhan strain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
  2. 3722
    “…Ex vivo culturing of isolated PBMCs from individuals vaccinated with the coronavirus disease 2019 (COVID-19) vaccine BNT162b1 revealed a pronounced T cell response in the presence of the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs
  3. 3723
    “…Anti-Region Binding Domain (anti-RBD) of the spike (S) protein immunoglobulin G (IgG) titers were measured by ELISA. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis
  4. 3724
    “…Considering individuals who were fully vaccinated with mRNA-based COVID-19 vaccines, the active treatment arm (n = 10) exhibited significantly higher serum levels of anti-RBD IgA (135 [32.9–976] BAU/ml vs 61.3 [26.7–97.1] BAU/ml, p = 0.036) than the placebo arm (n = 7) >28 days postvaccination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial
  5. 3725
    “…We measured total and neutralizing Ab responses to SARS-CoV-2 spike and RBD in sera, total anti-spike Abs in saliva, frequency of anti-RBD/NTD B cells, changes in frequency of anti-spike, HIV gag/nef-specific T cells, and HIV reservoirs in peripheral CD4(+) T cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV
  6. 3726
    “…Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
  7. 3727
    por Addetia, Amin, Piccoli, Luca, Case, James Brett, Park, Young-Jun, Beltramello, Martina, Guarino, Barbara, Dang, Ha, de Melo, Guilherme Dias, Pinto, Dora, Sprouse, Kaitlin, Scheaffer, Suzanne M., Bassi, Jessica, Silacci-Fregni, Chiara, Muoio, Francesco, Dini, Marco, Vincenzetti, Lucia, Acosta, Rima, Johnson, Daisy, Subramanian, Sambhavi, Saliba, Christian, Giurdanella, Martina, Lombardo, Gloria, Leoni, Giada, Culap, Katja, McAlister, Carley, Rajesh, Anushka, Dellota, Exequiel, Zhou, Jiayi, Farhat, Nisar, Bohan, Dana, Noack, Julia, Chen, Alex, Lempp, Florian A., Quispe, Joel, Kergoat, Lauriane, Larrous, Florence, Cameroni, Elisabetta, Whitener, Bradley, Giannini, Olivier, Cippà, Pietro, Ceschi, Alessandro, Ferrari, Paolo, Franzetti-Pellanda, Alessandra, Biggiogero, Maira, Garzoni, Christian, Zappi, Stephanie, Bernasconi, Luca, Kim, Min Jeong, Rosen, Laura E., Schnell, Gretja, Czudnochowski, Nadine, Benigni, Fabio, Franko, Nicholas, Logue, Jennifer K., Yoshiyama, Courtney, Stewart, Cameron, Chu, Helen, Bourhy, Hervé, Schmid, Michael A., Purcell, Lisa A., Snell, Gyorgy, Lanzavecchia, Antonio, Diamond, Michael S., Corti, Davide, Veesler, David
    Publicado 2023
    “…Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain(1) (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of vaccines and therapies remains poorly understood. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neutralization, effector function and immune imprinting of Omicron variants
  8. 3728
    “…The results show that our RT-QuIC assay can accurately detect α-synuclein seeding activity across the spectrum of Lewy Body (LB)-related disorders (LBD), including DLB, PD, iRBD, and PAF, with an overall sensitivity of 95.3%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies
  9. 3729
    “…Of the measured antibody responses, positivity for IgG against the SARS-CoV-2 spike receptor-binding domain (RBD) was predictive of survival rate, both in the presence or absence of diabetes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study
  10. 3730
    “…Analysis of cell viability revealed that neither the S1, S2 or a truncated form of the S1 containing only the RBD had minimal effects on hBMVEC viability within a 48 h exposure window. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier
  11. 3731
    “…We demonstrate that significant levels of anti-SARS-CoV-2 antibody to receptor binding domain (RBD), nucleocapsid, and spike S1 subunit of SARS-CoV-2 develop over the first 10 to 20 days of infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection
  12. 3732
    “…The glutamate (E) to Lysine (K) substitution at position 484 (E484K) in the receptor binding domain (RBD) of the spike protein is present in the rapidly spreading variants of concern belonging to the B.1.351 and P.1 lineages. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
  13. 3733
    “…IgG and IgA antibodies against SARS-CoV-2 RBD, S1, S2, and the nucleocapsid (N) protein, as well neutralization activity, were generally comparable between those participants that had asymptomatic infection or mild disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection
  14. 3734
    “…None of the serum samples analyzed were seroreactive based on an enzyme-linked immunosorbent assay (ELISA) using the receptor-binding domain (RBD) of the spike antigen. In this sense, no statistical difference was observed compared to the pre-pandemic sheep. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Absence of SARS-CoV-2 Antibodies in Natural Environment Exposure in Sheep in Close Contact with Humans
  15. 3735
    “…ND(50) titers positively correlated with plasma IgG targeting SARS-CoV-2 spike protein and RBD (r = 0.63 to 0.89), but moderately correlated with nucleoprotein IgG (r = 0.46 to 0.73). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
  16. 3736
    “…We measured circulating antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, ACE2 displacement and live viral neutralization activities one month following the first and second COVID-19 vaccine doses in 100 adult PLWH and 152 controls. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
  17. 3737
    “…At 200-300 days post PCR-verified infection, there was a wide variation in sensitivity between the commercial IgG-assays, ranging from <30% in the N-assay to >90% in the RBD-assay. There was only moderate agreement between NAbs and CD4(+) T-cell reactivity to S1 or SMN. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4(+) T-Cell Responses
  18. 3738
    “…Patients with MS treated with aCD20 lacking anti-RBD IgG had the most severe defect in circulating T(FH) responses and more robust CD8 T cell responses. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
  19. 3739
    “…MATERIALS AND METHODS: The study included 330 HCWs working at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
  20. 3740
    por Joyce, M. Gordon, Chen, Wei-Hung, Sankhala, Rajeshwer S., Hajduczki, Agnes, Thomas, Paul V., Choe, Misook, Martinez, Elizabeth J., Chang, William C., Peterson, Caroline E., Morrison, Elaine B., Smith, Clayton, Chen, Rita E., Ahmed, Aslaa, Wieczorek, Lindsay, Anderson, Alexander, Case, James Brett, Li, Yifan, Oertel, Therese, Rosado, Lorean, Ganesh, Akshaya, Whalen, Connor, Carmen, Joshua M., Mendez-Rivera, Letzibeth, Karch, Christopher P., Gohain, Neelakshi, Villar, Zuzana, McCurdy, David, Beck, Zoltan, Kim, Jiae, Shrivastava, Shikha, Jobe, Ousman, Dussupt, Vincent, Molnar, Sebastian, Tran, Ursula, Kannadka, Chandrika B., Soman, Sandrine, Kuklis, Caitlin, Zemil, Michelle, Khanh, Htet, Wu, Weimin, Cole, Matthew A., Duso, Debra K., Kummer, Larry W., Lang, Tricia J., Muncil, Shania E., Currier, Jeffrey R., Krebs, Shelly J., Polonis, Victoria R., Rajan, Saravanan, McTamney, Patrick M., Esser, Mark T., Reiley, William W., Rolland, Morgane, de Val, Natalia, Diamond, Michael S., Gromowski, Gregory D., Matyas, Gary R., Rao, Mangala, Michael, Nelson L., Modjarrad, Kayvon
    Publicado 2021
    “…A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID(50) > 10,000) following a single immunization, whereas RBD-ferritin nanoparticle (RFN) immunogens elicit similar responses after two immunizations and also show durable and potent neutralization against circulating VoCs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
Herramientas de búsqueda: RSS